Gene editing combinations for allogeneic car-t cells with enhanced immune evasion
AssigneeKite Pharma, Inc.
InventorsKatherine A. Freitas, Chloe Knights Krishnamurty, Geetha Boddu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides allogeneic cells that cause reduced risks of graft-versus-host disease (GVHD) and reduced risk of CD8 and NK cell rejections, for example, when used to treat diseases, such as cancer and/or autoimmune disease, in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of CD58, RFX5, ICAM1, FAS and/or TGFBR2. Methods of preparing and using such allogeneic cells are also provided.
Claims49
An isolated immune cell engineered to have CD58 expression or activity that is at least 10% lower as compared to a corresponding non-engineered immune cell and engineered to have FAS expression or activity that is at least 10% lower as compared to a corresponding non-engineered immune cell.
-46. (canceled)
An isolated immune cell engineered to have CD58 expression or activity that is at least 10% lower as compared to a corresponding non-engineered immune cell and engineered to have ICAM1 expression or activity that is at least 10% lower as compared to a corresponding non-engineered immune cell.
-83. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for preparing an allogeneic immune cell with reduced activity in inducing graft-versus-host disease (GVHD) or host rejection, comprising reducing, in the cell, the expression or activity of CD58 by at least 10% as compared to a corresponding non-engineered immune cell, further comprising reducing, in the cell, the expression or activity of FAS by at least 10% as compared to a corresponding non-engineered cell.
-115. (canceled)
-124. (canceled)
-133. (canceled)
A method for preparing an allogeneic immune cell with reduced activity in inducing graft-versus-host disease (GVHD) or host rejection, comprising reducing, in the cell, the expression or activity of CD58 by at least 10% as compared to a corresponding non-engineered immune cell, further comprising reducing, in the cell, the expression or activity of ICAM1 by at least 10% as compared to a corresponding non-engineered cell.
-167. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-182. (canceled)
-190. (canceled)
Dependencies are inferred from the claim text.